LifeMax Names Huang as Chief Medical Officer
5 May 2020 - - US-based orphan disease specialist LifeMax Laboratories, Inc has appointed Michael Huang, MD, as its chief medical officer, the company said.

LifeMax has several clinical stage programs. LM-030, licensed from Novartis and with fast track designation, rare pediatric disease designation and orphan drug designation, is in a Phase 2/3 trial for the treatment of Netherton syndrome.

AMB-051, licensed from Amgen through AmMax, its majority-owned subsidiary, and delivered via a patented technology, is in development as a best-in-class, well-differentiated and broadly applicable treatment for tenosynovial giant cell tumor.

Dr. Huang was most recently Chief Medical officer of Spruce Biosciences. He is an experienced biopharmaceutical industry executive who has successfully advanced therapeutics across modalities through all phases of development to regulatory approval.

He is the author or co-author of numerous peer-reviewed journal articles, abstracts, and scientific publications.

Huang received his bachelor's degree in molecular and cell biology from the University of California at Berkeley, his medical degree from the Chicago Medical School, and his post-graduate internship and residency training from the University of California at Irvine.

LifeMax Laboratories, Inc, a wholly-owned subsidiary of LifeMax Healthcare International Corp, is a clinical-stage biotech company focused on treating orphan diseases having few or no therapeutic options.